Portail HAL UNIV-RENNES
Not a member yet
180610 research outputs found
Sort by
Model-Based Clustering of Football Event Sequences: A Marked Spatio-Temporal Point Process Mixture Approach
No full textWe propose a novel mixture model for football event data that clusters entire possessions to reveal their temporal, sequential, and spatial structure. Each mixture component models possessions as marked spatio-temporal point processes: event types follow a finite Markov chain with an absorbing state for ball loss, event times follow a conditional Gamma process to account for dispersion, and spatial locations evolve via truncated Brownian motion. To aid interpretation, we derive summary indicators from model parameters capturing possession speed, number of events, and spatial dynamics. Parameters are estimated through maximum likelihood via Generalized Expectation-Maximization algorithm. Applied to StatsBomb data from 38 Ligue 1 matches (2020/2021), our approach uncovers distinct defensive possession patterns faced by Stade Rennais. Unlike previous approaches focusing on individual events, our mixture structure enables principled clustering of full possessions, supporting tactical analysis and the future development of realistic virtual training environments
Optimization of acquisition schemes towards a better estimation of microstructure parameters in diffusion MRI
No full textInternational audienc
Saisir la diversité à l’université : vers une approche socio-phénoménologique de l’expérience étudiante
No full textInternational audienc
Scoping Reviews (revues de portée) et Umbrella Review (revue de revue) : principe, méthodologie et pratique en santé au travail
No full textNational audienc
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (PRODIGE 62-FFCD 1701-OESIRI)
No full textInternational audienceBACKGROUND: Metastatic esophageal squamous cell carcinoma (mESCC) patients with disease progression after platinum-based first-line chemotherapy (CT) +/- immune checkpoint inhibitors (ICI) may benefit from second-line CT, mostly based on paclitaxel and irinotecan, but no randomized trial has compared these regimens. PATIENTS AND METHODS: PRODIGE 62-OESIRI is a multicenter, open-label, randomized phase II trial evaluating the efficacy and safety of nanoliposomal irinotecan (Nal-IRI) plus 5FU versus paclitaxel as second-line CT in mESCC. The primary endpoint was to achieve overall survival (OS) of 60 % at 9 months. RESULTS: Between March 2019 and July 2023, 106 pts were randomized. Median age was 65.6 years, 83.0 % men and 29.2 %/58.5 %/12.3 % of ECOG PS 0/1/2, respectively. As prior treatment, 48.6 % had chemoradiation, 41.9 % CT alone and 9.5 % CT plus ICI. OS at 9 months was 34.0 % [90 %CI: 22.9-46.5] and 39.2 % [90 %CI: 27.7-51.7] in the 5FU Nal-IRI and paclitaxel arms, respectively. The primary endpoint was not met. Median progression-free survival was 2.4 [95 %CI: 2.1-3.6] and 2.1 [95 %CI: 1.9-3.3] months, and median OS 7.1 [95 %CI: 5.2-8.3] and 6.6 [95 %CI: 4.8-10.3] months, respectively. Overall, 51.0 % and 38.5 % of patients experienced at least one grade 3-4 treatment-related adverse events (neuropathy: 2.0 vs. 7.7 %, diarrhea: 16.3 % vs. 0 % and vomiting: 10.2 vs. 0 %), in the 5FU Nal-IRI and paclitaxel arms, respectively. Treatment was discontinued for toxicity in 10.4 % versus 3.9 % in the 5FU Nal-IRI and paclitaxel arm, respectively. CONCLUSIONS: PRODIGE 62-OESIRI trial showed low efficacy of paclitaxel and 5FU Nal-IRI in the 2nd line treatment of mESCC, though paclitaxel provided a better safety profile. Trial registration NCT03719924
Transjugular Transcatheter Tricuspid Valve Replacement in Patients With Cardiac Implantable Electronic Devices
No full textInternational audienceBACKGROUND: Cardiac implantable electronic device (CIED)-related tricuspid regurgitation (TR) is common. Transcatheter tricuspid valve replacement (TTVR) is feasible with CIEDs in the right ventricle; however, data in this population are limited. OBJECTIVES: This study retrospectively analyzed patients undergoing compassionate-use transjugular TTVR with the LuX-Valve Plus for symptomatic TR with CIEDs from January 2022 to August 2024 at 17 international centers. METHODS: The primary endpoint was procedural TR reduction. Secondary endpoints included TR reduction, survival at 30 days, New York Heart Association functional class changes, and CIED function at follow-up. Non-CIED group was used for comparison. RESULTS: Of 99 patients, 36 (36.4%) had CIEDs. Baseline characteristics were similar, though the CIED group had a higher EuroSCORE (European System for Cardiac Operative Risk Evaluation) II score and more comorbidities. Procedural success (CIED vs non-CIED: 91.7% vs 95.2%; P = 0.781), 30-day mortality (5.6% vs 4.8%; P > 0.999), TR reduction (≤1+: 83.8% vs 84.9%; P > 0.999), and NYHA functional class I/II (80.8% vs 83.7%; P = 0.89) were comparable. The CIED cohort exhibited a higher numerical incidence of conversion to surgery (8.3% vs 1.6%) and tricuspid reintervention (11.5% vs 3.3%) within 6 months; however, these differences did not reach statistical significance (P = 0.267 and P = 0.160, respectively). Of the 22 patients with postoperative interrogation (median of 3.3 months), 9.1% of CIED patients exhibited worsening device parameters, with no need for lead replacement or extraction. CONCLUSIONS: Transjugular TTVR is safe and effective for managing TR and heart failure in patients with CIEDs. Due to the small sample size, these findings highlight the need for larger, prospective studies to validate these outcomes
Large responses to antidepressants or methodological artifacts? A secondary analysis of STAR*D, a single-arm, open-label, non-industry antidepressant trial
No full textInternational audienceOBJECTIVES: To replicate Stone et al.’s (2022) [1] finding that the distribution of response in clinical antidepressant trials is trimodal with large, medium-effect, and small subgroups. METHODS: To apply finite mixture modeling to pre-post Hamilton Depression Rating Scale (HDRS) differences (n = 2184) of STAR*D study’s level 1, a single-arm, open-label study. For a successful replication, the best fitting model had to be trimodal, with comparable components as in Stone et al. Secondary/sensitivity analyses repeated the analysis for different baseline levels of depression severity, imputed values, and patient-reported depression symptoms. RESULTS: The best fitting models were either bimodal or trimodal but the trimodal solution did not meet criteria for replication. The bimodal model had one component with HDRS mean change of M = -13.0, SD = 6.7 and included 65.3% of patients, and another component with M = -1.8, SD = 5.1, 34.7%, respectively. For the trimodal model, the component with the largest change (M = -14.3, SD = 6.4) applied to 52% of patients, which differed substantially from the large effect component in Stone et al. (M = -18.8, SD = 5.1) which applied to 7.2%. Secondary/sensitivity analyses arrived at similar conclusions and for patient-reported depression symptoms the best fitting models were unimodal or bimodal. CONCLUSIONS: This analysis failed to identify the trimodal distribution of response reported in Stone et al. In addition to being difficult to operationalize for regulatory purposes, results from mixture modeling are not sufficiently reliable to replace the more robust approach of comparing mean differences in depression rating scale scores between treatment arms
Reachability in multi-agent transfer systems (Extended Version)
No full textInternational audienceThis paper introduces collaborative reachability games with energy constraints. In the considered arenas, agents can spend or gain energy during moves, or share it with their peers if their current position allows it. We study several variants of energy reachability games where agents move either synchronously or asynchronously, and with/without constraints on energy transfers among peers. We show that these problems have dierent complexities ranging from NP to EXPSPACE